CROSS COUNTRY HEALTHCARE INC (CCRN) Fundamental Analysis & Valuation
NASDAQ:CCRN • US2274831047
9.78 USD
-0.07 (-0.71%)
At close: Mar 11, 2026
9.78 USD
0 (0%)
After Hours: 3/11/2026, 4:30:02 PM
This CCRN fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
Overall CCRN gets a fundamental rating of 4 out of 10. We evaluated CCRN against 101 industry peers in the Health Care Providers & Services industry. No worries on liquidiy or solvency for CCRN as it has an excellent financial health rating, but there are worries on the profitability. CCRN has a valuation in line with the averages, but it does not seem to be growing.
1. CCRN Profitability Analysis
1.1 Basic Checks
- CCRN had positive earnings in the past year.
- CCRN had a positive operating cash flow in the past year.
- In multiple years CCRN reported negative net income over the last 5 years.
- In multiple years CCRN reported negative operating cash flow during the last 5 years.
1.2 Ratios
- CCRN has a worse Return On Assets (-2.91%) than 60.40% of its industry peers.
- CCRN has a Return On Equity (-3.84%) which is in line with its industry peers.
- With a Return On Invested Capital value of 1.10%, CCRN is not doing good in the industry: 61.39% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -2.91% | ||
| ROE | -3.84% | ||
| ROIC | 1.1% |
ROA(3y)-4.3%
ROA(5y)5%
ROE(3y)-5.84%
ROE(5y)13.62%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- Looking at the Operating Margin, with a value of 0.56%, CCRN is doing worse than 61.39% of the companies in the same industry.
- CCRN has a Gross Margin (20.19%) which is in line with its industry peers.
- In the last couple of years the Gross Margin of CCRN has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 0.56% | ||
| PM (TTM) | N/A | ||
| GM | 20.19% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.25%
GM growth 5Y-3.52%
2. CCRN Health Analysis
2.1 Basic Checks
- The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so CCRN is destroying value.
- Compared to 1 year ago, CCRN has more shares outstanding
- CCRN has less shares outstanding than it did 5 years ago.
- CCRN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
- An Altman-Z score of 4.63 indicates that CCRN is not in any danger for bankruptcy at the moment.
- CCRN has a Altman-Z score of 4.63. This is amongst the best in the industry. CCRN outperforms 81.19% of its industry peers.
- There is no outstanding debt for CCRN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 4.63 |
ROIC/WACC0.13
WACC8.79%
2.3 Liquidity
- CCRN has a Current Ratio of 3.45. This indicates that CCRN is financially healthy and has no problem in meeting its short term obligations.
- CCRN has a Current ratio of 3.45. This is amongst the best in the industry. CCRN outperforms 86.14% of its industry peers.
- CCRN has a Quick Ratio of 3.45. This indicates that CCRN is financially healthy and has no problem in meeting its short term obligations.
- With an excellent Quick ratio value of 3.45, CCRN belongs to the best of the industry, outperforming 86.14% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.45 | ||
| Quick Ratio | 3.45 |
3. CCRN Growth Analysis
3.1 Past
- The earnings per share for CCRN have decreased strongly by -95.56% in the last year.
- CCRN shows a very negative growth in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -46.59% yearly.
- CCRN shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -21.56%.
- The Revenue has been growing slightly by 4.74% on average over the past years.
EPS 1Y (TTM)-95.56%
EPS 3Y-84.39%
EPS 5Y-46.59%
EPS Q2Q%-250%
Revenue 1Y (TTM)-21.56%
Revenue growth 3Y-27.85%
Revenue growth 5Y4.74%
Sales Q2Q%-23.61%
3.2 Future
- CCRN is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 128.64% yearly.
- CCRN is expected to show a decrease in Revenue. In the coming years, the Revenue will decrease by -0.64% yearly.
EPS Next Y388.12%
EPS Next 2Y128.64%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-5.4%
Revenue Next 2Y-0.64%
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
- When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
- The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. CCRN Valuation Analysis
4.1 Price/Earnings Ratio
- CCRN is valuated quite expensively with a Price/Earnings ratio of 489.00.
- CCRN's Price/Earnings is on the same level as the industry average.
- CCRN is valuated expensively when we compare the Price/Earnings ratio to 26.15, which is the current average of the S&P500 Index.
- Based on the Price/Forward Earnings ratio of 100.18, the valuation of CCRN can be described as expensive.
- CCRN's Price/Forward Earnings ratio is a bit more expensive when compared to the industry. CCRN is more expensive than 60.40% of the companies in the same industry.
- The average S&P500 Price/Forward Earnings ratio is at 24.27. CCRN is valued rather expensively when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 489 | ||
| Fwd PE | 100.18 |
4.2 Price Multiples
- Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of CCRN indicates a somewhat cheap valuation: CCRN is cheaper than 73.27% of the companies listed in the same industry.
- Compared to the rest of the industry, the Price/Free Cash Flow ratio of CCRN indicates a rather cheap valuation: CCRN is cheaper than 89.11% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 7.02 | ||
| EV/EBITDA | 9.47 |
4.3 Compensation for Growth
- The PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
- A more expensive valuation may be justified as CCRN's earnings are expected to grow with 128.64% in the coming years.
PEG (NY)1.26
PEG (5Y)N/A
EPS Next 2Y128.64%
EPS Next 3YN/A
5. CCRN Dividend Analysis
5.1 Amount
- No dividends for CCRN!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
CCRN Fundamentals: All Metrics, Ratios and Statistics
9.78
-0.07 (-0.71%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)03-04 2026-03-04/amc
Earnings (Next)05-05 2026-05-05/amc
Inst Owners84.61%
Inst Owner Change-19.96%
Ins Owners6.23%
Ins Owner Change11.51%
Market Cap320.39M
Revenue(TTM)1.05B
Net Income(TTM)-15.68M
Analysts70.67
Price Target11.6 (18.61%)
Short Float %4.29%
Short Ratio2.3
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-69.09%
Min EPS beat(2)-118.38%
Max EPS beat(2)-19.79%
EPS beat(4)1
Avg EPS beat(4)-49.67%
Min EPS beat(4)-118.38%
Max EPS beat(4)5.59%
EPS beat(8)4
Avg EPS beat(8)-23.71%
EPS beat(12)7
Avg EPS beat(12)-12.92%
EPS beat(16)11
Avg EPS beat(16)-6.6%
Revenue beat(2)0
Avg Revenue beat(2)-8.46%
Min Revenue beat(2)-9.46%
Max Revenue beat(2)-7.46%
Revenue beat(4)0
Avg Revenue beat(4)-5.87%
Min Revenue beat(4)-9.46%
Max Revenue beat(4)-0.73%
Revenue beat(8)1
Avg Revenue beat(8)-3.08%
Revenue beat(12)3
Avg Revenue beat(12)-1.76%
Revenue beat(16)6
Avg Revenue beat(16)-0.91%
PT rev (1m)-0.66%
PT rev (3m)-22.47%
EPS NQ rev (1m)-9.99%
EPS NQ rev (3m)15.38%
EPS NY rev (1m)0%
EPS NY rev (3m)-1.59%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-1.34%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.27%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 489 | ||
| Fwd PE | 100.18 | ||
| P/S | 0.28 | ||
| P/FCF | 7.02 | ||
| P/OCF | 5.91 | ||
| P/B | 0.79 | ||
| P/tB | 1.35 | ||
| EV/EBITDA | 9.47 |
EPS(TTM)0.02
EY0.2%
EPS(NY)0.1
Fwd EY1%
FCF(TTM)1.39
FCFY14.25%
OCF(TTM)1.66
OCFY16.93%
SpS34.42
BVpS12.46
TBVpS7.25
PEG (NY)1.26
PEG (5Y)N/A
Graham Number2.37
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -2.91% | ||
| ROE | -3.84% | ||
| ROCE | 1.39% | ||
| ROIC | 1.1% | ||
| ROICexc | 1.41% | ||
| ROICexgc | 2.72% | ||
| OM | 0.56% | ||
| PM (TTM) | N/A | ||
| GM | 20.19% | ||
| FCFM | 4.05% |
ROA(3y)-4.3%
ROA(5y)5%
ROE(3y)-5.84%
ROE(5y)13.62%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.25%
GM growth 5Y-3.52%
F-Score5
Asset Turnover2.09
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 49.56% | ||
| Cap/Sales | 0.76% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 229.81% | ||
| Profit Quality | N/A | ||
| Current Ratio | 3.45 | ||
| Quick Ratio | 3.45 | ||
| Altman-Z | 4.63 |
F-Score5
WACC8.79%
ROIC/WACC0.13
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-95.56%
EPS 3Y-84.39%
EPS 5Y-46.59%
EPS Q2Q%-250%
EPS Next Y388.12%
EPS Next 2Y128.64%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-21.56%
Revenue growth 3Y-27.85%
Revenue growth 5Y4.74%
Sales Q2Q%-23.61%
Revenue Next Year-5.4%
Revenue Next 2Y-0.64%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-52.34%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year297.63%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-53.83%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-49.76%
OCF growth 3YN/A
OCF growth 5YN/A
CROSS COUNTRY HEALTHCARE INC / CCRN FAQ
What is the ChartMill fundamental rating of CROSS COUNTRY HEALTHCARE INC (CCRN) stock?
ChartMill assigns a fundamental rating of 4 / 10 to CCRN.
What is the valuation status for CCRN stock?
ChartMill assigns a valuation rating of 4 / 10 to CROSS COUNTRY HEALTHCARE INC (CCRN). This can be considered as Fairly Valued.
Can you provide the profitability details for CROSS COUNTRY HEALTHCARE INC?
CROSS COUNTRY HEALTHCARE INC (CCRN) has a profitability rating of 2 / 10.
Can you provide the expected EPS growth for CCRN stock?
The Earnings per Share (EPS) of CROSS COUNTRY HEALTHCARE INC (CCRN) is expected to grow by 388.12% in the next year.